Syndax Pharmaceuticals (SNDX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Financial performance and product growth

• Achieved standout annual revenue with $125M in Revuforj sales and $152M in Niktimvo sales in the first 11 months on the market, both showing strong quarter-over-quarter growth.

• Revuforj saw 38% growth in Q4, driven by expanded indications and increased patient penetration, especially in KMT2A and NPM1.

• Maintenance therapy uptake in KMT2A patients post-transplant reached 35%-40%, with expectations to grow to 70%-80% over time.

• Both products are expected to continue meaningful expansion, with significant milestones anticipated through 2026.

• Operating expenses are being kept flat at $400M, supporting a clear path to profitability without additional funding needs.

Product development and clinical milestones

• Revuforj is expanding into new indications, including NPM1, with strong physician awareness and anticipation for broader use.

• Real-world and clinical data supporting maintenance therapy are being generated and will be presented at medical conferences in 2026.

• Revuforj is being explored for myeloproliferative neoplasms (MPN), with preclinical data showing promise and clinical trials planned.

• Niktimvo is approved for later-line chronic GVHD, with ongoing trials in earlier lines and combinations expected to read out in 2027 and 2028.

• IPF phase II trial for axatilimab is fully enrolled, with data expected in the second half of 2026; positive results could lead to phase III development.

Market strategy and partnerships

• Revuforj aims for dominant market share in both KMT2A and NPM1, leveraging best-in-class efficacy and physician education.

• Niktimvo's U.S. commercialization is a 50/50 profit split with Incyte, with 25%-30% of net sales recognized as collaboration revenue.

• Incyte is running key trials to expand Niktimvo's use in GVHD, including ex-U.S. markets.

• Collaboration with Incyte for IPF and other indications involves shared costs (55% Incyte, 45% partner) for future trials.

• Lifecycle management strategies are in place to maximize value from both franchises through new indications and global expansion.